You’ve heard of computer hacking, now meet gene hacking. In an age of remarkable health care innovation, scientists are manipulating human DNA to find new ways to treat diseases. Hear from our partners at Capital Group about this health care investment opportunity not called Ozempic…
They’ve moved from the lab to the real world with a treatment for the life-shortening disease sickle cell — the first approval based on a revolutionary gene-editing technology known as CRISPR.

“Whether it’s biotechnology or medical devices, there has always been an important moment that has changed how investors view a new technology or therapy. It could be one major success or a series of successes, and we are seeing pockets of that now across health care,” says Rich Wolf.

Read more here.
Looking for a portfolio with well-regarded investment options that are future thinking? Reach out to schedule your free investment review.

Your weekly market update is here.